التفاصيل البيبلوغرافية
| العنوان: |
Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings. |
| المؤلفون: |
Laich, Yannik1,2,3 (AUTHOR), Georgiou, Michalis1,2,4 (AUTHOR), Fujinami, Kaoru1,2,5 (AUTHOR), Daich Varela, Malena1,2 (AUTHOR), Fujinami-Yokokawa, Yu2,5,6 (AUTHOR), Hashem, Shaima Awadh1,2 (AUTHOR), Cabral de Guimaraes, Thales Antonio1,2 (AUTHOR), Mahroo, Omar A.1,2 (AUTHOR), Webster, Andrew R.1,2 (AUTHOR), Michaelides, Michel1,2 (AUTHOR) michel.michaelides@ucl.ac.uk |
| المصدر: |
Ophthalmology. Jul2024, Vol. 131 Issue 7, p845-854. 10p. |
| مصطلحات موضوعية: |
*MACULAR degeneration, *NATURAL history, *ENDOTHELIAL growth factors, *ANISOMETROPIA, *PHENOTYPIC plasticity, *VISUAL acuity, *HYPEROPIA |
| مستخلص: |
To analyze the genetic findings, clinical spectrum, and natural history of Best vitelliform macular dystrophy (BVMD) in a cohort of 222 children and adults. Single-center retrospective, consecutive, observational study. Patients with a clinical diagnosis of BVMD from pedigrees with a likely disease-causing monoallelic sequence variant in the BEST1 gene. Data were extracted from electronic and physical case notes. Electrophysiologic assessment and molecular genetic testing were analyzed. Molecular genetic test findings and clinical findings including best-corrected visual acuity (BCVA), choroidal neovascularization (CNV) rates, and electrophysiologic parameters. Two hundred twenty-two patients from 141 families were identified harboring 69 BEST1 variants. Mean age at presentation was 26.8 years (range, 1.3–84.8 years) and most patients (61.5%) demonstrated deterioration of central vision. Major funduscopic findings included 128 eyes (30.6%) with yellow vitelliform lesions, 78 eyes (18.7%) with atrophic changes, 49 eyes (11.7%) with fibrotic changes, 48 eyes (11.5%) with mild pigmentary changes, and 43 eyes (10.3%) showing a vitelliruptive appearance. Mean BCVA was 0.37 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/47) for the right eye and 0.33 logMAR (Snellen equivalent, 20/43) for the left eye at presentation, with a mean annual loss rate of 0.013 logMAR and 0.009 logMAR, respectively, over a mean follow-up of 9.7 years. Thirty-seven patients (17.3%) received a diagnosis of CNV over a mean follow-up of 8.0 years. Eyes with CNV that received treatment with an anti–vascular endothelial growth factor (VEGF) agent showed better mean BCVA compared with eyes that were not treated with an anti-VEGF agent (0.28 logMAR [Snellen equivalent, 20/38] vs. 0.62 logMAR [Snellen equivalent, 20/83]). Most eyes exhibited a hyperopic refractive error (78.7%), and 13 patients (6.1%) received a diagnosis of amblyopia. Among the 3 most common variants, p.(Ala243Val) was associated with a later age of onset, better age-adjusted BCVA, and less advanced Gass stages compared with p.(Arg218Cys) and p.(Arg218His). BVMD shows a wide spectrum of phenotypic variability. The disease is very slowly progressive, and the observed phenotype–genotype correlations allow for more accurate prognostication and counselling. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
